August 25, 2010
Bioniche & University of Ottawa Sign Exclusive Global License Agreement for Natural Health Technology

August 20, 2010
Additional Phase III Clinical Trial with UrocidinTM Expected to Commence in 2010

Check latest
stock price

All prices delayed at least 15 minutes.
Source: TSX Inc.

Corporate News Release

Bioniche Recognized with Québec Biotechnology Award

30/03/07

- Genesis award recognizes technology transfer and commercial success -

BELLEVILLE, ON, March 30, 2007 – Bioniche Life Sciences Inc. (TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced that it has received a Genesis Award from the Québec biotechnology, health technology and life science industry. The “Transfer-Emergence” award was presented to the Company last night in Montréal as part of the BIOMEDEX 2007 convention-exhibition.

This award is given to a company and its founding officers who have successfully implemented a technology transfer process and whose technology is characterized by innovation. Additionally, the company must:

• be experiencing commercial success, or showing considerable potential that is borne out by its licensing agreements or alliances;
• have extensive managerial, financial and scientific expertise;
• have transferred technology that is derived from a Canadian government or university.

“We are honoured to have received this award from the Québec biotechnology industry,” said Mr. Graeme McRae, President & CEO of Bioniche Life Sciences Inc. “It recognizes the significant achievements made by our company in the last year, with the initiation of our Phase III clinical trial with our proprietary Mycobacterial Cell Wall-DNA Complex (MCC) in human bladder cancer and the authorization of our E. coli O157:H7 food safety cattle vaccine for Canadian distribution.”

Bioniche Life Sciences Inc. has had a presence in Québec since 1997, when it set up research and development laboratories in Montréal. The Company’s human health business unit, Bioniche Therapeutics Limited, is based there. Approximately 40 employees work in pre-clinical and clinical research, and manufacturing.

Back

Categories:
All Releases
Archived Releases
Animal Health
Corporate
Financial
Food Safety
Human Health